In the preceding three months, 11 analysts have released ratings for Moderna (NASDAQ:MRNA), presenting a wide array of perspectives from bullish to bearish. The table below offers a condensed view ...

Looking at options history for Moderna (NASDAQ:MRNA) we detected 32 trades. If we consider the specifics of each trade, it is accurate to state that 25% of the investors opened trades with bullish ...

Moderna (NASDAQ:MRNA), the biotech company known for its Spikevax COVID-19 vaccine, released its fourth-quarter earnings on Feb. 14. The results revealed significant financial challenges as the ...

2025 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the fourth quarter and fiscal year 2024. "We have made progress in 2024 across our late-stage ...

Moderna MRNA incurred a loss of $2.50 per share in the fourth quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of $2.69. In the year-ago period, the company had reported ...

Moderna (MRNA) came out with a quarterly loss of $2.50 per share versus the Zacks Consensus Estimate of a loss of $2.69. This compares to earnings of $0.55 per share a year ago. These figures are ...

Barclays downgraded Moderna (NASDAQ:MRNA) to Equal Weight from Overweight in a note Tuesday, citing policy risks, a lack of major clinical catalysts, and macroeconomic uncertainties that limit the ...

MODERNA ($MRNA) posted quarterly earnings results on Friday, February 14th. The company reported earnings of -$2.50 per share, beating estimates of -$2.74 by $0.24 ...

(RTTNews) - Biotechnology company Moderna, Inc. (MRNA ... opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...

Moderna (MRNA) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook gives ...

We expect Moderna MRNA to surpass expectations when it reports fourth-quarter and full-year 2024 earnings on Feb. 14, before the opening bell. In the last reported quarter, MRNA’s earnings beat ...

Analysts on Wall Street project that Moderna (MRNA) will announce quarterly loss of $2.65 per share in its forthcoming report, representing a decline of 581.8% year over year. Revenues are ...